目的：分析高脂血症及降脂治疗对乙肝相关肝细胞癌病人术后预后的影响。方法：回顾性收集2012年1月至2021年1月于本院普外科手术的乙肝相关肝细胞癌病人，分析其血脂水平和相关降脂治疗对乙肝相关肝细胞癌病人术后预后的影响。结果：166例乙肝相关肝细胞癌病人中高脂血症63例，其中33例使用他汀类药物。高脂血症组术后中位无病生存时间明显低于正常血脂组（24.8个月对比38.5个月，P<0.05），高脂血症组中位总生存期也明显低于正常血脂组（30.1个月对比44.5个月，P<0.05）。高脂血症病人使用他汀类药物后（中位无病生存时间为23.4个月，中位总体生存时间为29.7个月），与未使用的高脂血症病人（中位无病生存时间为26.3个月，中位总体生存时间为30.3个月）的预后差异无统计学意义。结论：乙肝相关肝细胞癌病人高脂血症是其术后无病生存和总生存的危险因素，但在高脂血症病人中单纯使用他汀类药物降脂并不能减少其复发风险,延长生存时间。

Objective To explore the effect of hyperlipidemia and lipid-lowering therapy on the prognosis of postoperative patients with hepatitis B related hepatocellular carcinoma. Methods The clinical data of the patients with hepatitis B related hepatocellular carcinoma who were operated in our hospital from January 2012 to January 2021 were retrospectively collected. The effect of blood lipid level and related lipid-lowering therapy on the prognosis of postoperative patients with hepatitis B related hepatocellular carcinoma was analyzed. Results Among 166 patients with hepatitis B related hepatocellular carcinoma, there were 63 cases had hyperlipidemia, of which 33 cases were treated by statins. The median postoperative disease free survival time in the hyperlipidemia group was significantly lower than that in the normal blood lipid group (24.8 months vs. 38.5 months, P<0.05), and the median overall survival time in the hyperlipidemia group was also significantly lower than that in the normal blood lipid group (30.1 months vs. 44.5 months, P<0.05). There was no statistically significant difference in prognosis between the patients with hyperlipidemia who used statins or not. The median disease free survival time was 23.4 months vs. 26.3 months, and the median overall survival time was 29.7 months vs. 30.3 months. Conclusions Hyperlipidemia is a risk factor for disease free survival and overall survival after surgery in the patients with hepatitis B related hepatocellular carcinoma. The use of statins alone in hyperlipidemia patients cannot reduce the risk of recurrence and prolong survival time.